U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07533942) titled 'A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma' on April 10.
Brief Summary: This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Meningioma
Intervention:
DRUG: JZP3507
Participants will receive oral JZP3507 monotherapy twice daily, on 3 consecutive days per week in 28-day cycles.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jazz Pharmaceuticals
Disclaimer: Curated by HT Syndication....